Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

3.98
0.0000
Post-market: 3.990.0102+0.26%17:57 EST
Volume:14.13M
Turnover:55.74M
Market Cap:2.07B
PE:-2.23
High:4.00
Open:3.95
Low:3.85
Close:3.98
52wk High:12.36
52wk Low:3.54
Shares:519.84M
Float Shares:415.00M
Volume Ratio:0.49
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7839
EPS(LYR):-1.6909
ROE:-91.06%
ROA:-42.04%
PB:1.98
PE(LYR):-2.35

Loading ...

11 Stocks That Have Cratered and Look Like Buys -- Barrons.com

Dow Jones
·
3 hours ago

Nvidia Concept Stocks Rally. Applied Digital And CoreWeave Up 7%; Nebius Up 6%; Nvidia And Core Scientific Up 3%; WeRide Up 2%

Tiger Newspress
·
Yesterday

Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook

Simply Wall St.
·
Yesterday

Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares

Reuters
·
Feb 07

Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors

TIPRANKS
·
Feb 07

The Genesis Mission Has a 270-Day Timeline – And You’re Already Late

InvestorPlace
·
Jan 27

Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage?

Simply Wall St.
·
Jan 23

Director Christopher Gibson Sells Common Shares of Recursion Pharmaceuticals Inc

Reuters
·
Jan 23

Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness

Simply Wall St.
·
Jan 17

Nvidia Concept Stocks Rally. CoreWeave Up 8%; Recursion Up 4%; Nebius Up 3%; WeRide And Applied Digital Up 2%; SoundHound Up 1%

Tiger Newspress
·
Jan 12

Recursion Updates AI Drug Platform, Financial Outlook at JPM

TIPRANKS
·
Jan 12

Recursion Pharmaceuticals Files Initial Beneficial Ownership Statement for CSO David Hallett

Reuters
·
Jan 10

Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares

Reuters
·
Jan 08

Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC

Simply Wall St.
·
Jan 05

Getty Images, Torm, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Jan 03

Recursion CFO Ben R. Taylor Reports Sale of Common Shares

Reuters
·
Dec 31, 2025

Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares

Reuters
·
Dec 30, 2025

3 Small AI Plays to Buy for 2026

Benzinga_recent_news
·
Dec 27, 2025

Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares

Reuters
·
Dec 20, 2025

Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades

Simply Wall St.
·
Dec 19, 2025